Clin2
NCT07715747Possibly a fitNot yet recruiting

Testing a new drug for advanced solid tumors with CLDN6

Solid TumorMetastatic Ovary CancerMetastatic Gastric CancerMetastatic Endometrial Carcinoma

Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.

This trial tests a new drug called TJ037130 for people with advanced solid tumors that have a specific protein called Claudin 6 (CLDN6) on their cells. The goal is to see if the drug is safe and works against the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
128 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • Your cancer is advanced and has spread, and no standard treatments are available or working.
  • Your tumor has a protein called Claudin 6 (CLDN6), confirmed by a lab test.
  • You have recovered from side effects of earlier treatments (except for things like hair loss or stable thyroid issues).
  • You are healthy enough to be up and about (ECOG score 0 or 1).
  • You agree to use effective birth control during the study and for 6 months after treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06809114Recruiting· Phase 1
Study of AT03-65 for advanced CLDN6-positive solid tumors

This early-phase trial tests an investigational drug (AT03-65) for people with advanced solid tumors that have a certain protein called CLDN6. The goal is to see if the drug is safe and if it might help shrink tumors.

Portland, Oregon
NCT07304128Recruiting· Phase 1
PLB-002 for advanced solid tumors study

This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.

Shanghai, Shanghai Municipality
NCT07595237Recruiting· Early Phase 1
Radioactive treatment for advanced solid tumors with Claudin18.2

This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.

Shanghai, Shanghai Municipality
NCT06276491Recruiting· Phase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker

This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.

Duarte, California
NCT06223256Recruiting· Phase 1
NBL-028 for advanced solid tumors with CLDN6

This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.

Shijiazhuang, Hebei
NCT06446388Not yet recruiting· Phase 2
Study of two new drugs plus chemo for advanced Claudin18.2-positive tumors

This trial tests a combination of two new study drugs (QLS31905 and QL1706) plus chemotherapy against advanced solid tumors that have a specific protein called Claudin18.2. It's for people who have not had any prior treatment for their advanced cancer.

Beijing, Beijing Municipality

Hear when a new Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.